Background: A link between androgen use and the risk of cancers, especially prostate and breast cancer, has been suggested. The knowledge about a possible association is limited.
Objective: The study aimed to investigate cancer incidence rates, particularly those related to prostate and breast cancer, in male androgen users and compare them to a control group.
Methods: We included male androgen users identified through a nationwide anti-doping testing program in Danish fitness centers from 2006 to 2018. We paired each case with 50 male controls of the same age, selected randomly. The cohort was followed from baseline and until 2023. The outcome was the incidence of prostate cancer, breast cancer, or any cancer excluding non-melanoma skin cancer.
Results: The study included 1,189 androgen users and 59,450 controls, with a mean age of 27 years at enrolment. During the follow-up period with a mean length of 11 years, 13 androgen users, and 612 controls were diagnosed with cancer. This resulted in an incidence rate ratio of 1.05 (95% CI: 0.55-1.81). None of the androgen users were diagnosed with prostate or breast cancer.
Discussion And Conclusion: Male androgen users did not face an increased short-term risk of cancer, neither overall nor related to prostate or breast cancer. Our study indicates that the absolute risk of malignancies in androgen users is comparable to that in the background population. However, we cannot exclude androgens as a cancer risk factor due to the limited sample size, relatively short follow-up period, and subject age.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/andr.13648 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma and salivary hormone responses to a 30-min exercise stress test in young, healthy, physically active females.
Physiol Rep
December 2024
SHAPE Research Centre, Department of Sport Science, Nottingham Trent University, Nottingham, UK.
Overreaching, a consequence of intensified training, is used by athletes to enhance performance. A blunted hormonal response to a 30-min interval exercise stress test (55/80) has been shown in males after intensified training, highlighting cortisol and testosterone as potential biomarkers of overreaching. Despite accounting for ~50% of the population, studies into hormonal responses to exercise in females are lacking.
View Article and Find Full Text PDFDaily life mobility detects frailty, falls, and functioning in older prostate cancer survivors treated with androgen deprivation therapy.
J Geriatr Oncol
December 2024
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, USA. Electronic address:
Introduction: Androgen deprivation therapy (ADT) increases the risk of frailty, falls, and poor physical functioning in older adults with prostate cancer. Detection of frailty is limited to self-report instruments and performance measures, so unbiased tools are needed. We investigated relationships between an unbiased measure - daily life mobility - and ADT history, frailty, fall history, and functioning in older prostate cancer survivors treated with ADT.
View Article and Find Full Text PDFInternational PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women's health condition.
EClinicalMedicine
December 2024
Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC, Australia.
Article Synopsis
- Polycystic ovary syndrome (PCOS) is a prevalent health issue that can lead to various reproductive, metabolic, and psychological problems, highlighting the need for a collective approach to establish research priorities in this field.
- A comprehensive process involving international surveys, systematic reviews, and peer validation revealed over 150 key research priorities, focusing on diagnosis, care models, patient information, lifestyle management, and fertility treatments for those with PCOS.
- The resulting clinical research roadmap aims to direct future studies according to the needs and interests of women with PCOS and healthcare providers, addressing this commonly overlooked condition.
Little evidence based information exists in the medical literature on the mortality of abusers of anabolic androgenic steroids. These individuals range from competitive athletes and body builders to those whose who use physician prescribed mega-doses. Life insurance medical directors have little guidance on how to underwrite these individuals when presented with their applications.
View Article and Find Full Text PDFSexual function following risk-reducing salpingo-oophorectomy: a prospective cohort study.
Sex Med
October 2024
Department of Women's and Children's Health, Karolinska Institutet, 117 77 Stockholm, Sweden.
Background: Increased access to and indications for genetic testing will lead to more women undergoing risk-reducing salpingo-oophorectomy (RRSO), with a potential impact on sexual function.
Aim: Our objective was to prospectively investigate (1) sexual function in women with pathogenic variant (PV) in genes, before and 1 year after RRSO, and to compare with a healthy age-matched control group and (2) to study if testosterone levels correlate with sexual functioning after RRSO.
Methods: A prospective observational follow-up study of 43 -PV carriers planned for RRSO and 73 healthy-age matched controls.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!